These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 33974236)

  • 21. LXR activation potentiates sorafenib sensitivity in HCC by activating microRNA-378a transcription.
    Lin Z; Xia S; Liang Y; Ji L; Pan Y; Jiang S; Wan Z; Tao L; Chen J; Lin C; Liang X; Xu J; Cai X
    Theranostics; 2020; 10(19):8834-8850. PubMed ID: 32754282
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways.
    Xu Y; Huang J; Ma L; Shan J; Shen J; Yang Z; Liu L; Luo Y; Yao C; Qian C
    Cancer Lett; 2016 Feb; 371(2):171-81. PubMed ID: 26655273
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting Hedgehog signalling in CD133-positive hepatocellular carcinoma: improving Lenvatinib therapeutic efficiency.
    Hu Q; Hu X; Zhang L; Zhao Y; Li L
    Med Oncol; 2021 Mar; 38(4):41. PubMed ID: 33730237
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TRERNA1 upregulation mediated by HBx promotes sorafenib resistance and cell proliferation in HCC via targeting NRAS by sponging miR-22-3p.
    Song W; Zheng C; Liu M; Xu Y; Qian Y; Zhang Z; Su H; Li X; Wu H; Gong P; Li Y; Fan H
    Mol Ther; 2021 Aug; 29(8):2601-2616. PubMed ID: 33839325
    [TBL] [Abstract][Full Text] [Related]  

  • 25. DEAD-Box Helicase 17 circRNA (circDDX17) Reduces Sorafenib Resistance and Tumorigenesis in Hepatocellular Carcinoma.
    Zhang X; Wang W; Mo S; Sun X
    Dig Dis Sci; 2024 Jun; 69(6):2096-2108. PubMed ID: 38653946
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A positive feedback loop involving the LINC00346/β-catenin/MYC axis promotes hepatocellular carcinoma development.
    Zhang N; Chen X
    Cell Oncol (Dordr); 2020 Feb; 43(1):137-153. PubMed ID: 31691159
    [TBL] [Abstract][Full Text] [Related]  

  • 27. NQO1 Mediates Lenvatinib Resistance by Regulating ROS-induced Apoptosis in Hepatocellular Carcinoma.
    Xue W; Wang T; Tian WJ; Pang SQ; Zhang HF; Jia WD
    Curr Med Sci; 2024 Feb; 44(1):168-179. PubMed ID: 38217831
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pregnane X receptor mediates sorafenib resistance in advanced hepatocellular carcinoma.
    Feng F; Jiang Q; Cao S; Cao Y; Li R; Shen L; Zhu H; Wang T; Sun L; Liang E; Sun H; Chai Y; Li X; Liu G; Yang R; Yang Z; Yang Y; Xin S; Li BA
    Biochim Biophys Acta Gen Subj; 2018 Apr; 1862(4):1017-1030. PubMed ID: 29369785
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The lncRNA lnc-TSI antagonizes sorafenib resistance in hepatocellular carcinoma via downregulating miR-4726-5p expression and upregulating KCNMA1 expression.
    Chen F; Jiang J; Liu D; Li H; Dong L; Song Y; Zhang Y; Wang J; Qin Y; Zhao G
    J Mol Histol; 2024 Feb; 55(1):83-96. PubMed ID: 38165571
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.
    Liang Y; Zheng T; Song R; Wang J; Yin D; Wang L; Liu H; Tian L; Fang X; Meng X; Jiang H; Liu J; Liu L
    Hepatology; 2013 May; 57(5):1847-57. PubMed ID: 23299930
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antitumor Effect of Lenvatinib Combined with Alisertib in Hepatocellular Carcinoma by Targeting the DNA Damage Pathway.
    Hao J; Peng Q; Wang K; Yu G; Pan Y; Du X; Hu N; Zhang X; Qin Y; Li H
    Biomed Res Int; 2021; 2021():6613439. PubMed ID: 34337035
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Exosomes derived from miR-122-modified adipose tissue-derived MSCs increase chemosensitivity of hepatocellular carcinoma.
    Lou G; Song X; Yang F; Wu S; Wang J; Chen Z; Liu Y
    J Hematol Oncol; 2015 Oct; 8():122. PubMed ID: 26514126
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Exosomal lncRNA H19 promotes the progression of hepatocellular carcinoma treated with Propofol via miR-520a-3p/LIMK1 axis.
    Wang D; Xing N; Yang T; Liu J; Zhao H; He J; Ai Y; Yang J
    Cancer Med; 2020 Oct; 9(19):7218-7230. PubMed ID: 32767662
    [TBL] [Abstract][Full Text] [Related]  

  • 34. LncRNA HCG18 contributes to the progression of hepatocellular carcinoma via miR-214-3p/CENPM axis.
    Zou Y; Sun Z; Sun S
    J Biochem; 2020 Nov; 168(5):535-546. PubMed ID: 32663252
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model.
    Kimura T; Kato Y; Ozawa Y; Kodama K; Ito J; Ichikawa K; Yamada K; Hori Y; Tabata K; Takase K; Matsui J; Funahashi Y; Nomoto K
    Cancer Sci; 2018 Dec; 109(12):3993-4002. PubMed ID: 30447042
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long noncoding RNA UPK1A-AS1 indicates poor prognosis of hepatocellular carcinoma and promotes cell proliferation through interaction with EZH2.
    Zhang DY; Sun QC; Zou XJ; Song Y; Li WW; Guo ZQ; Liu SS; Liu L; Wu DH
    J Exp Clin Cancer Res; 2020 Oct; 39(1):229. PubMed ID: 33121524
    [TBL] [Abstract][Full Text] [Related]  

  • 37. LncSNHG3 promotes hepatocellular carcinoma epithelial mesenchymal transition progression through the miR-152-3p/JAK1 pathway.
    Li H; Wu Y; Wang R; Guo J; Yu Q; Zhang L; Zhao H; Yang H
    Genes Genomics; 2022 Jan; 44(1):133-144. PubMed ID: 34778942
    [TBL] [Abstract][Full Text] [Related]  

  • 38. USP22-JMJD8 axis promotes Lenvatinib resistance in hepatocellular carcinoma.
    Guo J; Zhao J
    Biochim Biophys Acta Mol Cell Res; 2024 Jan; 1871(1):119617. PubMed ID: 37898375
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MiRNA-124-3p.1 sensitizes hepatocellular carcinoma cells to sorafenib by regulating FOXO3a by targeting AKT2 and SIRT1.
    Dong ZB; Wu HM; He YC; Huang ZT; Weng YH; Li H; Liang C; Yu WM; Chen W
    Cell Death Dis; 2022 Jan; 13(1):35. PubMed ID: 35013144
    [TBL] [Abstract][Full Text] [Related]  

  • 40. N
    Xu J; Wan Z; Tang M; Lin Z; Jiang S; Ji L; Gorshkov K; Mao Q; Xia S; Cen D; Zheng J; Liang X; Cai X
    Mol Cancer; 2020 Nov; 19(1):163. PubMed ID: 33222692
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.